ERBB2 and breast cancer: This article highlights the latest evidence of neoadjuvant and adjuvant treatments for patients diagnosed with HER2+ BC and includes the following: chemotherapy with or without anthracycline, single or dual blockage agents against HER2, and an optimal therapy duration.